Swedish rare-disease specialist Sobi is paying $75 million upfront for global commercial rights to Innate Pharma’s lacutamab, a first-in-class antibody targeting KIR3DL2 in cutaneous T-cell lymphoma. The deal gives Innate funding and a commercial partner for its next clinical step, while adding a late-stage oncology asset to Sobi’s rare-disease portfolio.
Swedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3
Latest NewsSwedish rare-disease specialist Sobi is paying $75 million upfront for global commercial rights to Innate Pharma’s lacutamab, a first-in-class antibody targeting KIR3DL2 in cutaneous T-cell lymphoma. The deal gives Innate funding and a commercial partner for its next clinical step, while adding a late-stage oncology asset to Sobi’s rare-disease portfolio.
Clinical Development Expert has started
AppointmentsLondon-based EpilepsyGTx has appointed Dr Teresa Nunes as Chief Medical Officer (CMO) to support the continued development of the company’s gene therapy program, including its progression toward clinical development.
Actimed retrieves ALS drug after Faraday collapse
Latest NewsUK biotech Actimed Therapeutics has regained global rights to S-oxprenolol from the now-defunct Faraday Pharmaceuticals, giving it control of the experimental muscle-wasting drug across cancer cachexia, amyotrophic lateral sclerosis (ALS) and other potential indications.
Mironid lands $46M Series B to take kidney drug into clinic
Latest NewsScottish biotech Mironid has raised $46 million (€40 million) in a Series B financing to advance MR-L45, its small-molecule candidate for autosomal dominant polycystic kidney disease (ADPKD) through clinical development.
Evexta pairs ex-Merck drug with Roche’s giredestrant
Latest NewsFrench biotech Evexta Bio will combine its rupitasertib with Roche’s giredestrant in a Phase 1b trial targeting second-line, ESR1-mutated advanced breast cancer.
AstraZeneca taps Pathos for breast cancer degrader
Latest NewsAstraZeneca has put Pathos AI in charge of the early clinical development of AZD4241, its preclinical ERα degrader for ER-positive, HER2-negative breast cancer, under a co-exclusive licensing agreement.
Ipsen quietly returns cancer drug IPN01194 to AGV Discovery
Latest NewsIpsen confirmed to European Biotechnology that it has stopped developing the Phase 1/2a ERK inhibitor IPN01194 and will return worldwide rights to French biotech AGV Discovery.
Sobi’s dealmaker CEO exits for BioNTech
Latest NewsGuido Oelkers will leave Swedish Orphan Biovitrum to become BioNTech’s CEO by Feb. 1, 2027, succeeding co-founder Uğur Şahin after overseeing a nine-year transformation that increased Sobi’s revenue more than fivefold.
AstraZeneca explores $400B combination with BMS
Latest NewsAstraZeneca has held talks with Bristol Myers Squibb over a potential combination that would create a pharmaceutical group worth nearly $400 billion (€348 billion), the Financial Times reported.
ZEUS failure clouds future of Novo’s cardiovascular plans
Latest NewsNovo Nordisk’s ziltivekimab failed to reduce cardiovascular events in a Phase 3 trial, dealing a blow to a drug once forecast to generate about $3 billion in peak annual sales.